Literature DB >> 19409696

Effect of pro-inflammatory cytokine stimulation on human breast cancer: implications of chemokine receptor expression in cancer metastasis.

Julio E Valdivia-Silva1, Janusz Franco-Barraza, Ana Luisa Esparza Silva, Gisela Du Pont, Gloria Soldevila, Isaura Meza, Eduardo A García-Zepeda.   

Abstract

Interactions between tumour cells and microenvironments may affect their growth and metastasis formation. In search for a better understanding of the role of cellular mediators in the progression of cancer, we investigated the effect of pro-inflammatory cytokines IL-1, IL-6, TNF-alpha and IFN-gamma on the regulation of expression of chemokine receptors CXCR4, CXCR2, CX3CR1, CCR9, and CCR5 in the human breast cancer cell line MCF-7. Our results showed that IL-1 increased CXCR4 expression whereas TNF-alpha increased CX3CR1, CCR9 and CCR5. Interestingly, this regulation was not homogeneous, emphasizing the inherent heterogeneity in cancer that may be responsive to specific inflammatory microenvironments.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19409696     DOI: 10.1016/j.canlet.2009.03.040

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  16 in total

1.  Angiotensin-converting enzyme inhibition down-regulates the pro-atherogenic chemokine receptor 9 (CCR9)-chemokine ligand 25 (CCL25) axis.

Authors:  Joshua Abd Alla; Andreas Langer; Sherif S Elzahwy; Gökhan Arman-Kalcek; Thomas Streichert; Ursula Quitterer
Journal:  J Biol Chem       Date:  2010-05-26       Impact factor: 5.157

2.  The Tumor-Promoting Flow of Cells Into, Within and Out of the Tumor Site: Regulation by the Inflammatory Axis of TNFα and Chemokines.

Authors:  Adit Ben-Baruch
Journal:  Cancer Microenviron       Date:  2011-12-22

Review 3.  The wound healing, chronic fibrosis, and cancer progression triad.

Authors:  Brad Rybinski; Janusz Franco-Barraza; Edna Cukierman
Journal:  Physiol Genomics       Date:  2014-02-11       Impact factor: 3.107

4.  Fibroblast growth factor receptor 1 activation in mammary tumor cells promotes macrophage recruitment in a CX3CL1-dependent manner.

Authors:  Johanna R Reed; Matthew D Stone; Thomas C Beadnell; Yungil Ryu; Timothy J Griffin; Kathryn L Schwertfeger
Journal:  PLoS One       Date:  2012-09-24       Impact factor: 3.240

5.  Selection of a MCF-7 Breast Cancer Cell Subpopulation with High Sensitivity to IL-1β: Characterization of and Correlation between Morphological and Molecular Changes Leading to Increased Invasiveness.

Authors:  Eloy Andres Pérez-Yépez; Jorge-Tonatiuh Ayala-Sumuano; Alicia Maria Reveles-Espinoza; Isaura Meza
Journal:  Int J Breast Cancer       Date:  2012-05-10

6.  Leptin pro-angiogenic signature in breast cancer is linked to IL-1 signalling.

Authors:  W Zhou; S Guo; R R Gonzalez-Perez
Journal:  Br J Cancer       Date:  2010-12-07       Impact factor: 7.640

7.  Extracellular NM23 Signaling in Breast Cancer: Incommodus Verum.

Authors:  Iain L O Buxton; Nucharee Yokdang
Journal:  Cancers (Basel)       Date:  2011-09       Impact factor: 6.639

Review 8.  Chemokine-Derived Peptides: Novel Antimicrobial and Antineoplasic Agents.

Authors:  Julio Valdivia-Silva; Jaciel Medina-Tamayo; Eduardo A Garcia-Zepeda
Journal:  Int J Mol Sci       Date:  2015-06-08       Impact factor: 5.923

9.  Deficiency of C-C chemokine receptor 5 suppresses tumor development via inactivation of NF-κB and upregulation of IL-1Ra in melanoma model.

Authors:  Ju Kyoung Song; Mi Hee Park; Dong-Young Choi; Hwan Soo Yoo; Sang Bae Han; Do Young Yoon; Jin Tae Hong
Journal:  PLoS One       Date:  2012-05-02       Impact factor: 3.240

10.  Evaluating the Association between CCR5delta32 Polymorphism (rs333) and the Risk of Breast Cancer in a Cohort of Iranian Population.

Authors:  Amir Tajbakhsh; Zahra Farjami; Abolfazl Nesaei-Bajestani; Fahimeh Afzaljavan; Mahdi Rivandi; Atefeh Moezzi; Soheila Abedini; Mahla Asghari; Mohammad Mahdi Kooshyar; Fatemeh Homaei Shandiz; Alireza Pasdar
Journal:  Iran J Public Health       Date:  2021-03       Impact factor: 1.429

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.